Molecular and vascular targets in the pathogenesis and management of the hypertension associated with preeclampsia

Cardiovascular and Hematological Agents in Medicinal Chemistry

Volumn 8, Issue 4, 2010, Pages 204-226

  Reslan, Ossama M ^a   Khalil, Raouf A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Blood pressure; Endothelium; Preeclampsia; Pregnancy; Vascular smooth muscle

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANGIOTENSIN II ANTIBODY; ANTIHYPERTENSIVE AGENT; ARGININE; ASCORBIC ACID; CALCIUM; CYTOKINE; DIAZOXIDE; ENDOTHELIN 1; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; FAS LIGAND; FISH OIL; HEPARIN; HLA ANTIGEN CLASS 1; HYDRALAZINE; HYPOXIA INDUCIBLE FACTOR; INTRACELLULAR CALCIUM SENSING PROTEIN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LOW MOLECULAR WEIGHT HEPARIN; MAGNESIUM; MAGNESIUM SULFATE; MATRIX METALLOPROTEINASE; NIFEDIPINE; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; RHO KINASE; THROMBOXANE A2; UNINDEXED DRUG; ZINC;

AMNIOCENTESIS; AMNION FLUID; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE; CALCIUM DEFICIENCY; CHLAMYDIAL PNEUMONIA; CLINICAL TRIAL; COMORBIDITY; CYTOKINE RELEASE; CYTOMEGALOVIRUS; CYTOTROPHOBLAST; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DIET; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DOPPLER ECHOGRAPHY; ECLAMPSIA; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; ETHNICITY; EXTRACELLULAR MATRIX; EXTRACHROMOSOMAL INHERITANCE; FETUS MORTALITY; GENE INTERACTION; GENE MAPPING; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENOME IMPRINTING; HAPLOTYPE; HEADACHE; HELLP SYNDROME; HETEROZYGOTE; HUMAN; HYPERTENSION; IMMUNE RESPONSE; IMMUNE SYSTEM; INFLAMMATION; INTRAUTERINE GROWTH RETARDATION; ISCHEMIA; LOW DRUG DOSE; MATERNAL CARE; MATERNAL MORTALITY; NATURAL KILLER CELL; OBESITY; PAPILLEDEMA; PATHOGENESIS; PERFUSION PRESSURE; PLACENTA ISCHEMIA; PREECLAMPSIA; PREGNANCY COMPLICATION; PRENATAL CARE; PROTEIN POLYMORPHISM; PROTEINURIA; REDUCED UTEROPLACENTAL PERFUSION PRESSURE; REPRODUCTION; RISK BENEFIT ANALYSIS; RISK FACTOR; SEIZURE; SMOOTH MUSCLE CONTRACTION; SOLUTIO PLACENTAE; THROMBOCYTE COUNT; UTERINE ARTERY; VASCULAR ENDOTHELIUM; VASCULAR RESISTANCE; VASOCONSTRICTION; VIRUS INFECTION; VISUAL DISORDER; VITAMIN D DEFICIENCY;

ANIMALS; FEMALE; GENOMIC IMPRINTING; HUMANS; HYPERTENSION; MALE; MICE; PRE-ECLAMPSIA; PREGNANCY; RATS; RISK FACTORS;

EID: 77958486591     PISSN: 18715257     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152510792481234     Document Type: Article

References (239)

1. Roberts, J.M.; Gammill, H.S. Preeclampsia: recent insights. Hypertension, 2005, 46(6), 1243-1249.
2. Winn, V.D.; Gormley, M.; Paquet, A.C.; Kjaer-Sorensen, K.; Kramer, A.; Rumer, K.K.; Haimov-Kochman, R.; Yeh, R.F.; Overgaard, M.T.; Varki, A.; Oxvig, C.; Fisher, S.J. Severe preeclampsia-related changes in gene expression at the maternal-fetal interface include sialic acid-binding immunoglobulin-like lectin-6 and pappalysin-2. Endocrinology, 2009, 150(1), 452-462.
3. Redman, C.W.; Sargent, I.L. Latest advances in understanding preeclampsia. Science, 2005, 308(5728), 1592-1594.
4. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet. Gynecol., 2002, 99(1), 159-167.
5. Stennett, A.K.; Khalil, R.A. Neurovascular mechanisms of hypertension in pregnancy. Curr. Neurovasc. Res., 2006, 3(2), 131-148.
6. Maynard, S.; Epstein, F.H.; Karumanchi, S.A. Preeclampsia and angiogenic imbalance. Annu. Rev. Med., 2008, 59, 61-78.
7. Sholook, M.M.; Gilbert, J.S.; Sedeek, M.H.; Huang, M.; Hester, R.L.; Granger, J.P. Systemic hemodynamic and regional blood flow changes in response to chronic reductions in uterine perfusion pressure in pregnant rats. Am. J. Physiol. Heart Circ. Physiol., 2007, 293(4), H2080-2084.
8. Tinsley, J.H.; Chiasson, V.L.; South, S.; Mahajan, A.; Mitchell, B.M. Immunosuppression improves blood pressure and endothelial function in a rat model of pregnancy-induced hypertension. Am. J. Hypertens., 2009, 22(10), 1107-1114.
9. Sibai, B.M. Thrombophilia and severe preeclampsia: time to screen and treat in future pregnancies? Hypertension, 2005, 46(6), 1252-1253.
10. Haig, D. Genetic conflicts in human pregnancy. Q Rev. Biol., 1993, 68(4), 495-532.
11. Dekker, G.; Sibai, B. Primary, secondary, and tertiary prevention of pre-eclampsia. Lancet, 2001, 357(9251), 209-215.
12. Basso, O.; Rasmussen, S.; Weinberg, C.R.; Wilcox, A.J.; Irgens, M.; Skjaerven, R. Trends in fetal and infant survival following preeclampsia. JAMA, 2006, 296(11), 1357-1362.
13. Nilsson, E.; Salonen Ros, H.; Cnattingius, S.; Lichtenstein, P. The importance of genetic and environmental effects for pre-eclampsia and gestational hypertension: a family study. BJOG, 2004, 111(3), 200-206.
14. Cnattingius, S.; Reilly, M.; Pawitan, Y.; Lichtenstein, P. Maternal and fetal genetic factors account for most of familial aggregation of preeclampsia: a population-based Swedish cohort study. Am. J. Med. Genet. A, 2004, 130A(4), 365-371.
15. Cross, J.C. The genetics of pre-eclampsia: a feto-placental or maternal problem? Clin. Genet., 2003, 64(2), 96-103.
16. Laivuori, H.; Lahermo, P.; Ollikainen, V.; Widen, E.; Haiva-Mallinen, L.; Sundstrom, H.; Laitinen, T.; Kaaja, R.; Ylikorkala, O.; Kere, J. Susceptibility loci for preeclampsia on chromosomes 2p25 and 9p13 in Finnish families. Am. J. Hum. Genet., 2003, 72(1), 168-177.
17. Founds, S.A.; Conley, Y.P.; Lyons-Weiler, J.F.; Jeyabalan, A.; Hogge, W.A.; Conrad, K.P. Altered global gene expression in first trimester placentas of women destined to develop preeclampsia. Placenta, 2009, 30(1), 15-24.
18. Papazoglou, D.; Galazios, G.; Koukourakis, M.I.; Kontomanolis, E.N.; Maltezos, E. Association of -634G/C and 936C/T polymorphisms of the vascular endothelial growth factor with spontaneous preterm delivery. Acta Obstet. Gynecol. Scand., 2004, 83(5), 461-465.
19. Rajakumar, A.; Michael, H.M.; Daftary, A.; Jeyabalan, A.; Gilmour, C.; Conrad, K.P. Proteasomal activity in placentas from women with preeclampsia and intrauterine growth restriction: implications for expression of HIF-alpha proteins. Placenta, 2008, 29(3), 290-299.
20. Ciarmela, P.; Boschi, S.; Bloise, E.; Marozio, L.; Benedetto, C.; Castellucci, M.; Petraglia, F. Polymorphisms of FAS and FAS ligand genes in preeclamptic women. Eur. J. Obstet. Gynecol. Reprod. Biol., 2010, 148(2), 144-146.
21. Muy-Rivera, M.; Ning, Y.; Frederic, I.O.; Vadachkoria, S.; Luthy, D.A.; Williams, M.A. Leptin, soluble leptin receptor and leptin gene polymorphism in relation to preeclampsia risk. Physiol. Res., 2005, 54(2), 167-174.
22. Zafarmand, M.H.; Franx, A.; Sabour, S.; van der Schouw, Y.T.; Grobbee, D.E.; de Leeuw, P.W.; Bots, M.L. The M235T variant of the angiotensinogen gene is related to development of self-reported hypertension during pregnancy: the Prospect-EPIC cohort study. Hypertens. Res., 2008, 31(7), 1299-1305.
23. Duckers, C.; Simioni, P.; Spiezia, L.; Radu, C.; Gavasso, S.; Rosing, J.; Castoldi, E. Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency. Blood, 2008, 112(9), 3615-3623.
24. Mayor-Olea, A.; Callejon, G.; Palomares, A.R.; Jimenez, A.J.; Gaitan, M.J.; Rodriguez, A.; Ruiz, M.; Reyes-Engel, A. Human genetic selection on the MTHFR 677C>T polymorphism. BMC Med. Genet., 2008, 9, 104.
25. Piccoli, J.C.; Gottlieb, M.G.; Castro, L.; Bodanese, L.C.; Manenti, E.R.; Bogo, M.R.; Peres, A.; Rocha, M.I.; Cruz, I.B. Association between 894G>T endothelial nitric oxide synthase gene polymorphisms and metabolic syndrome. Arq. Bras. Endocrinol. Metabol., 2008, 52(8), 1367-1373.
26. Nishizawa, H.; Pryor-Koishi, K.; Suzuki, M.; Kato, T.; Kogo, H.; Sekiya, T.; Kurahashi, H.; Udagawa, Y. Increased levels of pregnancy-associated plasma protein-A2 in the serum of pre-eclamptic patients. Mol. Hum. Reprod., 2008, 14(10), 595-602.
27. Fitzpatrick, E.; Goring, H.H.; Liu, H.; Borg, A.; Forrest, S.; Cooper, D.W.; Brennecke, S.P.; Moses, E.K. Fine mapping and SNP analysis of positional candidates at the preeclampsia susceptibility locus (PREG1) on chromosome 2. Hum. Biol., 2004, 76(6), 849-862.
28. Brinkman-Van der Linden, E.C.; Hurtado-Ziola, N.; Hayaawa, T.; Wiggleton, L.; Benirschke, K.; Varki, A.; Varki, N. Humanspecific expression of Siglec-6 in the placenta. Glycobiology, 2007, 17(9), 922-931.
29. Ward, K. Searching for genetic factors underlying pre-eclampsia: recent progress and persistent challenges. Minerva Ginecol., 2008, 60(5), 399-419.
30. Tan, C.Y.; Chong, Y.S.; Loganath, A.; Chan, Y.H.; Ravichandran, J.; Lee, C.G.; Chong, S.S. Possible gene-gene interaction of KIR2DL4 with its cognate ligand HLA-G in modulating risk for preeclampsia. Reprod. Sci., 2009, 16(12), 1135-1143.
31. Lie, R.T.; Rasmussen, S.; Brunborg, H.; Gjessing, H.K.; Lie-Nielsen, E.; Irgens, L.M. Fetal and maternal contributions to risk of pre-eclampsia: population based study. BMJ, 1998, 316(7141), 1343-1347.
32. Esplin, M.S.; Fausett, M.B.; Fraser, A.; Kerber, R.; Mineau, G.; Carrillo, J.; Varner, M.W. Paternal and maternal components of the predisposition to preeclampsia. N. Engl. J. Med., 2001, 344(12), 867-872
33. Massardier, J.; Golfier, F.; Journet, D.; Frappart, L.; Zalaquett, M.; Schott, A.M.; Lenoir, V.T.; Dupuis, O.; Hajri, T.; Raudrant, D. Twin pregnancy with complete hydatidiform mole and coexistent fetus: obstetrical and oncological outcomes in a series of 14 cases. Eur. J. Obstet. Gynecol. Reprod. Biol., 2009, 143(2), 84-87.
34. Rosenberg, T.J.; Garbers, S.; Lipkind, H.; Chiasson, M.A. Maternal obesity and diabetes as risk factors for adverse pregnancy outcomes: differences among 4 racial/ethnic groups. Am. J. Public Health, 2005, 95(9), 1545-1551.
35. Caughey, A.B.; Stotland, N.E.; Washington, A.E.; Escobar, G.J. Maternal ethnicity, paternal ethnicity, and parental ethnic discordance: predictors of preeclampsia. Obstet. Gynecol., 2005, 106(1), 156-161.
36. Adamova, Z.; Ozkan, S.; Khalil, R.A. Vascular and cellular calcium in normal and hypertensive pregnancy. Curr. Clin. Pharmacol., 2009, 4(3), 172-190.
37. Bucher, H.C.; Guyatt, G.H.; Cook, R.J.; Hatala, R.; Cook, D.J.; Lang, J.D.; Hunt, D. Effect of calcium supplementation on pregnancy-induced hypertension and preeclampsia: a meta-analysis of randomized controlled trials. JAMA, 1996, 275(14), 1113-1117.
38. Kumar, A.; Devi, S.G.; Batra, S.; Singh, C.; Shukla, D.K. Calcium supplementation for the prevention of pre-eclampsia. Int. J. Gynaecol. Obstet., 2009, 104(1), 32-36.
39. Levine, R.J.; Hauth, J.C.; Curet, L.B.; Sibai, B.M.; Catalano, P.M.; Morris, C.D.; DerSimonian, R.; Esterlitz, J.R.; Raymond, E.G.; Bild, D.E.; Clemens, J.D.; Cutler, J.A. Trial of calcium to prevent preeclampsia. N. Engl. J. Med., 1997, 337(2), 69-76.
40. Prada, J.A.; Tsang, R.C.; Clark, K.E. Hypocalcemia and pregnancy-induced hypertension produced by low-calcium diet. Hypertension, 1994, 23(6 Pt 1), 695-702.
41. Aiko, A.; Ito, M.; Okamura, H.; Araki, H.; Nishi, K. Effect of a low calcium intake on the vascular sensitivity to angiotensin II in normotensive pregnant rats. Artery, 1992, 19(4), 199-210.
42. Ezimokhai, M.; Osman, N. Calcium sup plementation is associated with endothelium dependent attenuation of vascular smooth muscle reactivity in normotensive pregnant and nonpregnant rats. Am. J. Hypertens., 1998, 11(1 Pt 1), 88-96.
43. Roberts, J.M.; Balk, J.L.; Bodnar, L.M.; Belizan, J.M.; Bergel, E.; Martinez, A. Nutrient involvement in preeclampsia. J. Nutr., 2003, 133(5 Suppl. 2), 1684S-1692S.
44. Frederick, I.O.; Williams, M.A.; Dashow, E.; Kestin, M.; Zhang, C.; Leisenring, W.M. Dietary fiber, potassium, magnesium and calcium in relation to the risk of preeclampsia. J. Reprod. Med., 2005, 50(5), 332-344.
45. Bodnar, L.M.; Catov, J.M.; Simhan, H.N.; Holick, M.F.; Powers, R.W.; Roberts, J.M. Maternal vitamin D deficiency increases the risk of preeclampsia. J. Clin. Endocrinol. Metab., 2007, 92(9), 3517-3522.
46. Halhali, A.; Diaz, L.; Avila, E.; Ariza, A.C.; Garabedian, M.; Larrea, F. Decreased fractional urinary calcium excretion and serum 1,25-dihydroxyvitamin D and IGF-I levels in preeclampsia. J. Steroid Biochem. Mol. Biol., 2007, 103(3-5), 803-806.
47. Li, Y.C.; Kong, J.; Wei, M.; Chen, Z.F.; Liu, S.Q.; Cao, L.P. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J. Clin. Invest., 2002, 110(2), 229-238.
48. Holmes, V.A.; McCance, D.R. Could antioxidant supplementation prevent pre-eclampsia? Proc. Nutr. Soc., 2005, 64(4), 491-501.
49. Title, L.M.; Ur, E.; Giddens, K.; McQueen, M.J.; Nassar, B.A. Folic acid improves endothelial dysfunction in type 2 diabetes-an effect independent of homocysteine-lowering. Vasc. Med., 2006, 11(2), 101-109.
50. Wen, S.W.; Chen, X.K.; Rodger, M.; White, R.R.; Yang, Q.; Smith, G.N.; Sigal, R.J.; Perkins, S.L.; Walker, M.C. Folic acid supplementation in early second trimester and the risk of preeclampsia. Am. J. Obstet. Gynecol., 2008, 198(1), 45 e41-e47.
51. Flegal, K.M.; Carroll, M.D.; Ogden, C.L.; Johnson, C.L. Prevalence and trends in obesity among US adults, 1999-2000. JAMA, 2002, 288(14), 1723-1727.
52. Villamor, E.; Cnattingius, S. Interpregnancy weight change and risk of adverse pregnancy outcomes: a population-based study. Lancet, 2006, 368(9542), 1164-1170.
53. Stone, J.L.; Lockwood, C.J.; Berkowitz, G.S.; Alvarez, M.; Lapinski, R.; Berkowitz, R.L. Risk factors for severe preeclampsia. Obstet. Gynecol., 1994, 83(3), 357-361.
54. Clement, K.; Viguerie, N.; Poitou, C.; Carette, C.; Pelloux, V.; Curat, C.A.; Sicard, A.; Rome, S.; Benis, A.; Zucker, J.D.; Vidal, H.; Laville, M.; Barsh, G.S.; Basdevant, A.; Stich, V.; Cancello, R.; Langin, D. Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects. FASEB J., 2004, 18(14), 1657-1669.
55. Hendler, I.; Blackwell, S.C.; Mehta, S.H.; Whitty, J.E.; Russell, E.; Sorokin, Y.; Cotton, D.B. The levels of leptin, adiponectin, and resistin in normal weight, overweight, and obese pregnant women with and without preeclampsia. Am. J. Obstet. Gynecol., 2005, 193(3 Pt 2), 979-983.
56. Leddy, M.A.; Power, M.L.; Schulkin, J. The impact of maternal obesity on maternal and fetal health. Rev. Obstet. Gynecol., 2008, 1(4), 170-178.
57. Montoro, M.N.; Kjos, S.L.; Chandler, M.; Peters, R.K.; Xiang, A.H.; Buchanan, T.A. Insulin resistance and preeclampsia in gestational diabetes mellitus. Diabetes Care, 2005, 28(8), 1995-2000.
58. Bartha, J.L.; Gonzalez-Bugatto, F.; Fernandez-Macias, R.; Gonzalez-Gonzalez, N.L.; Comino-Delgado, R.; Hervias-Vivancos, B. Metabolic syndrome in normal and complicated pregnancies. Eur. J. Obstet. Gynecol. Reprod. Biol., 2008, 137(2), 178-184.
59. Becker, T.; Vermeulen, M.J.; Wyatt, P.R.; Meier, C.; Ray, J.G. Prepregnancy diabetes and risk of placental vascular disease. Diabetes Care, 2007, 30(10), 2496-2498.
60. Carpenter, M.W. Gestational diabetes, pregnancy hypertension, and late vascular disease. Diabetes Care, 2007, 30(Suppl. 2), S246-250.
61. Wang, J.X.; Knottnerus, A.M.; Schuit, G.; Norman, R.J.; Chan, A.; Dekker, G.A. Surgically obtained sperm, and risk of gestational hypertension and pre-eclampsia. Lancet, 2002, 359(9307), 673-674.
62. Saito, S.; Shiozaki, A.; Nakashima, A.; Sakai, M.; Sasaki, Y. The role of the immune system in preeclampsia. Mol. Aspects Med., 2007, 28(2), 192-209.
63. Tafuri, A.; Alferink, J.; Moller, P.; Hammerling, G.J.; Arnold, B. T cell awareness of paternal alloantigens during pregnancy. Science, 1995, 270(5236), 630-633.
64. Koelman, C.A.; Coumans, A.B.; Nijman, H.W.; Doxiadis, II; Dekker, G.A.; Claas, F.H. Correlation between oral sex and a low incidence of preeclampsia: a role for soluble HLA in seminal fluid? J. Reprod. Immunol., 2000, 46(2), 155-166.
65. Robertson, S.A.; Bromfield, J.J.; Tremellen, K.P. Seminal 'priming' for protection from pre-eclampsia-a unifying hypothesis. J. Reprod. Immunol., 2003, 59(2), 253-265.
66. Hanna, J.; Goldman-Wohl, D.; Hamani, Y.; Avraham, I.; Greenfield, C.; Natanson-Yaron, S.; Prus, D.; Cohen-Daniel, L.; Arnon, T.I.; Manaster, I.; Gazit, R.; Yutkin, V.; Benharroch, D.; Porgador, A.; Keshet, E.; Yagel, S.; Mandelboim, O. Decidual NK cells regulate key developmental processes at the human fetalmaternal interface. Nat. Med., 2006, 12(9), 1065-1074.
67. Sibai, B.; Dekker, G.; Kupferminc, M. Pre-eclampsia. Lancet, 2005, 365(9461), 785-799.
68. Le Bouteiller, P.; Pizzato, N.; Barakonyi, A.; Solier, C. HLA-G, pre-eclampsia, immunity and vascular events. J. Reprod. Immunol., 2003, 59(2), 219-234.
69. von Dadelszen, P.; Magee, L.A.; Krajden, M.; Alasaly, K.; Popovska, V.; Devarakonda, R.M.; Money, D.M.; Patrick, D.M.; Brunham, R.C. Levels of antibodies against cytomegalovirus and Chlamydophila pneumoniae are increased in early onset preeclampsia. BJOG, 2003, 110(8), 725-730.
70. Trogstad, L.I.; Eskild, A.; Bruu, A.L.; Jeansson, S.; Jenum, P.A. Is preeclampsia an infectious disease? Acta Obstet. Gynecol. Scand., 2001, 80(11), 1036-1038.
71. Kusanovic, J.P.; Romero, R.; Hassan, S.S.; Gotsch, F.; Edwin, S.; Chaiworapongsa, T.; Erez, O.; Mittal, P.; Mazaki-Tovi, S.; Soto, E.; Than, N.G.; Friel, L.A.; Yoon, B.H.; Espinoza, J. Maternal serum soluble CD30 is increased in normal pregnancy, but decreased in preeclampsia and small for gestational age pregnancies. J. Matern. Fetal Neonatal Med., 2007, 20(12), 867-878.
72. Geva, E.; Ginzinger, D.G.; Zaloudek, C.J.; Moore, D.H.; Byrne, A.; Jaffe, R.B. Human placental vascular development: vasculogenic and angiogenic (branching and nonbranching) transformation is regulated by vascular endothelial growth factor-A, angiopoietin-1, and angiopoietin-2. J. Clin. Endocrinol. Metab., 2002, 87(9), 4213-4224.
73. McMaster, M.T.; Zhou, Y.; Fisher, S.J. Abnormal placentation and the syndrome of preeclampsia. Semin. Nephrol., 2004, 24(6), 540-547.
74. Genbacev, O.; DiFederico, E.; McMaster, M.; Fisher, S.J. Invasive cytotrophoblast apoptosis in pre-eclampsia. Hum. Reprod., 1999, 14(Suppl. 2), 59-66.
75. Chaddha, V.; Viero, S.; Huppertz, B.; Kingdom, J. Developmental biology of the placenta and the origins of placental insufficiency. Semin. Fetal Neonatal Med., 2004, 9(5), 357-369.
76. Levine, R.J.; Lam, C.; Qian, C.; Yu, K.F.; Maynard, S.E.; Sachs, B.P.; Sibai, B.M.; Epstein, F.H.; Romero, R.; Thadhani, R.; Karumanchi, S.A. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N. Engl. J. Med., 2006, 355(10), 992-1005.
77. Gilbert, J.S.; Gilbert, S.A.; Arany, M.; Granger, J.P. Hypertension produced by placental ischemia in pregnant rats is associated with increased soluble endoglin expression. Hypertension, 2009, 53(2), 399-403.
78. Chen, W.; Khalil, R.A. Differential [Ca2+]i signaling of vasoconstriction in mesenteric microvessels of normal and reduced uterine perfusion pregnant rats. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2008, 295(6), R1962-R1972.
79. Walsh, S.K.; English, F.A.; Johns, E.J.; Kenny, L.C. Plasmamediated vascular dysfunction in the reduced uterine perfusion pressure model of preeclampsia: a microvascular characterization. Hypertension, 2009, 54(2), 345-351.
80. Orshal, J.M.; Khalil, R.A. Reduced endothelial NO-cGMPmediated vascular relaxation and hypertension in IL-6-infused pregnant rats. Hypertension, 2004, 43(2), 434-444.
81. Murphy, J.G.; Fleming, J.B.; Cockrell, K.L.; Granger, J.P.; Khalil, R.A. [Ca(2+)](i) signaling in renal arterial smooth muscle cells of pregnant rat is enhanced during inhibition of NOS. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2001, 280(1), R87-R99.
82. Crews, J.K.; Novak, J.; Granger, J.P.; Khalil, R.A. Stimulated mechanisms of Ca2+ entry into vascular smooth muscle during NO synthesis inhibition in pregnant rats. Am. J. Physiol., 1999, 276(2 Pt 2), R530-538.
83. Kanasaki, K.; Palmsten, K.; Sugimoto, H.; Ahmad, S.; Hamano, Y.; Xie, L.; Parry, S.; Augustin, H.G.; Gattone, V.H.; Folkman, J.; Strauss, J.F.; Kalluri, R. Deficiency in catechol-Omethyltransferase and 2-methoxyoestradiol is associated with preeclampsia. Nature, 2008, 453(7198), 1117-1121.
84. Shaarawy, M.; Al-Sokkary, F.; Sheba, M.; Wahba, O.; Kandil, H.O.; Abdel-Mohsen, I. Angiogenin and vascular endothelial growth factor in pregnancies complicated by preeclampsia. Int. J. Gynaecol. Obstet., 2005, 88(2), 112-117.
85. Stepan, H.; Faber, R.; Dornhofer, N.; Huppertz, B.; Robitzki, A.; Walther, T. New insights into the biology of preeclampsia. Biol. Reprod., 2006, 74(5), 772-776.
86. Hayashi, M.; Ueda, Y.; Yamaguchi, T.; Sohma, R.; Shibazaki, M.; Ohkura, T.; Inaba, N. Tumor necrosis factor-alpha in the placenta is not elevated in pre-eclamptic patients despite its elevation in peripheral blood. Am. J. Reprod. Immunol., 2005, 53(3), 113-119.
87. Casart, Y.C.; Tarrazzi, K.; Camejo, M.I. Serum levels of interleukin-6, interleukin-1beta and human chorionic gonadotropin in preeclamptic and normal pregnancy. Gynecol. Endocrinol., 2007, 23(5), 300-303.
88. Tsukimori, K.; Fukushima, K.; Tsushima, A.; Nakano, H. Generation of reactive oxygen species by neutrophils and endothelial cell injury in normal and preeclamptic pregnancies. Hypertension, 2005, 46(4), 696-700.
89. Montagnana, M.; Lippi, G.; Albiero, A.; Scevarolli, S.; Salvagno, G.L.; Franchi, M.; Guidi, G.C. Evaluation of metalloproteinases 2 and 9 and their inhibitors in physiologic and pre-eclamptic pregnancy. J. Clin. Lab. Anal., 2009, 23(2), 88-92.
90. Ranta, V.; Viinikka, L.; Halmesmaki, E.; Ylikorkala, O. Nitric oxide production with preeclampsia. Obstet. Gynecol., 1999, 93(3), 442-445.
91. Mills, J.L.; DerSimonian, R.; Raymond, E.; Morrow, J.D.; Roberts, L.J., 2nd; Clemens, J.D.; Hauth, J.C.; Catalano, P.; Sibai, B.; Curet, L.B.; Levine, R.J. Prostacyclin and thromboxane changes predating clinical onset of preeclampsia: a multicenter prospective study. JAMA, 1999, 282(4), 356-362.
92. Kenny, L.C.; Baker, P.N.; Kendall, D.A.; Randall, M.D.; Dunn, W.R. Differential mechanisms of endothelium-dependent vasodilator responses in human myometrial small arteries in normal pregnancyand pre-eclampsia. Clin. Sci. (Lond)., 2002, 103(1), 67-73.
93. Clark, B.A.; Halvorson, L.; Sachs, B.; Epstein, F.H. Plasma endothelin levels in preeclampsia: elevation and correlation with uric acid levels and renal impairment. Am. J. Obstet. Gynecol., 1992, 166(3), 962-968.
94. Brosnihan, K.B.; Neves, L.A.; Anton, L.; Joyner, J.; Valdes, G.; Merrill, D.C. Enhanced expression of Ang-(1-7) during pregnancy. Braz. J. Med. Biol. Res., 2004, 37(8), 1255-1262.
95. Maynard, S.E.; Min, J.Y.; Merchan, J.; Lim, K.H.; Li, J.; Mondal, S.; Libermann, T.A.; Morgan, J.P.; Sellke, F.W.; Stillman, I.E.; Epstein, F.H.; Sukhatme, V.P.; Karumanchi, S.A. Excess placental soluble fms-like tyrosine kinase 1 (s Flt1) may contribute to endo thelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest., 2003, 111(5), 649-658.
96. LaMarca, B.D.; Ryan, M.J.; Gilbert, J.S.; Murphy, S.R.; Granger, J.P. Inflammatory cytokines in the pathophysiology of hypertension during preeclampsia. Curr. Hypertens. Rep., 2007, 9(6), 480-485.
97. Gilbert, J.S.; Ryan, M.J.; LaMarca, B.B.; Sedeek, M.; Murphy, S.R.; Granger, J.P. Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am. J. Physiol. Heart Circ. Physiol., 2008, 294(2), H541-550.
98. Alexander, B.T.; Kassab, S.E.; Miller, M.T.; Abram, S.R.; Reckelhoff, J.F.; Bennett, W.A.; Granger, J.P. Reduced uterine perfusion pressure during pregnancy in the rat is associated with increases in arterial pressure and changes in renal nitric oxide. Hypertension, 2001, 37(4), 1191-1195.
99. Wang, Y.P.; Walsh, S.W.; Guo, J.D.; Zhang, J.Y. Maternal levels of prostacyclin, thromboxane, vitamin E, and lipid peroxides throughout normal pregnancy. Am. J. Obstet. Gynecol., 1991, 165(6 Pt 1), 1690-1694.
100. LaMarca, B.B.; Cockrell, K.; Sullivan, E.; Bennett, W.; Granger, J.P. Role of endothelin in mediating tumor necrosis factor-induced hypertension in pregnant rats. Hypertension, 2005, 46(1), 82-86.
101. LaMarca, B.; Parrish, M.; Ray, L.F.; Murphy, S.R.; Roberts, L.; Glover, P.; Wallukat, G.; Wenzel, K.; Cockrell, K.; Martin, J.N., Jr.; Ryan, M.J.; Dechend, R. Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1. Hypertension, 2009, 54(4), 905-909.
102. 2+]i in renal arterial smooth muscle cells of pregnant rats with reduced uterine perfusion pressure. Am. J. Physiol. Heart Circ. Physiol., 2003, 284(1), H393-403.
103. Ferrara, N.; Houck, K.; Jakeman, L.; Leung, D.W. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr. Rev., 1992, 13(1), 18-32.
104. Serraf, A.; Aznag, H.; Baudet, B.; Detruit, H.; Seccatore, F.; Mazmanian, M.G.; Planche, C. Pulmonary vascular endothelial growth factor and nitric oxide interaction during total cardiopulmonary bypass in neonatal pigs. J. Thorac. Cardiovasc. Surg., 2003, 125(5), 1050-1057.
105. Vincenti, V.; Cassano, C.; Rocchi, M.; Persico, G. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation, 1996, 93(8), 1493-1495.
106. Kupferminc, M.J.; Daniel, Y.; Englender, T.; Baram, A.; Many, A.; Jaffa, A.J.; Gull, I.; Lessing, J.B. Vascular endothelial growth factor is increased in patients with preeclampsia. Am. J. Reprod. Immunol., 1997, 38(4), 302-306.
107. Eremina, V.; Jefferson, J.A.; Kowalewska, J.; Hochster, H.; Haas, M.; Weisstuch, J.; Richardson, C.; Kopp, J.B.; Kabir, M.G.; Backx, P.H.; Gerber, H.P.; Ferrara, N.; Barisoni, L.; Alpers, C.E.; Quaggin, S.E. VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med., 2008, 358(11), 1129-1136.
108. Sugimoto, H.; Hamano, Y.; Charytan, D.; Cosgrove, D.; Kieran, M.; Sudhakar, A.; Kalluri, R. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J. Biol. Chem., 2003, 278(15), 12605-12608.
109. Ahmad, S.; Ahmed, A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ. Res., 2004, 95(9), 884-891.
110. Clark, D.E.; Smith, S.K.; He, Y.; Day, K.A.; Licence, D.R.; Corps, A.N.; Lammoglia, R.; Charnock-Jones, D.S. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol. Reprod., 1998, 59(6), 1540-1548.
111. Maynard, S.E.; Moore Simas, T.A.; Solitro, M.J.; Rajan, A.; Crawford, S.; Soderland, P.; Meyer, B.A. Circulating angiogenic factors in singleton vs multiple-gestation pregnancies. Am. J. Obstet. Gynecol., 2008, 198(2), 200. e1-e7.
112. Bdolah, Y.; Lam, C.; Rajakumar, A.; Shivalingappa, V.; Mutter, W.; Sachs, B.P.; Lim, K.H.; Bdolah-Abram, T.; Epstein, F.H.; Karumanchi, S.A. Twin pregnancy and the risk of preeclampsia: bigger placenta or relative ischemia? Am. J. Obstet. Gynecol., 2008, 198(4), 428. e1-e6.
113. Bdolah, Y.; Palomaki, G.E.; Yaron, Y.; Bdolah-Abram, T.; Goldman, M.; Levine, R.J.; Sachs, B.P.; Haddow, J.E.; Karumanchi, S.A. Circulating angiogenic proteins in trisomy 13. Am. J. Obstet. Gynecol., 2006, 194(1), 239-245.
114. Cheifetz, S.; Bellon, T.; Cales, C.; Vera, S.; Bernabeu, C.; Massague, J.; Letarte, M. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J. Biol. Chem., 1992, 267(27), 19027-19030.
115. Venkatesha, S.; Toporsian, M.; Lam, C.; Hanai, J.; Mammoto, T.; Kim, Y.M.; Bdolah, Y.; Lim, K.H.; Yuan, H.T.; Libermann, T.A.; Stillman, I.E.; Roberts, D.; D'Amore, P.A.; Epstein, F.H.; Sellke, F.W.; Romero, R.; Sukhatme, V.P.; Letarte, M.; Karumanchi, S.A. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat. Med., 2006, 12(6), 642-649.
116. Osol, G.; Celia, G.; Gokina, N.; Barron, C.; Chien, E.; Mandala, M.; Luksha, L.; Kublickiene, K. Placental growth factor is a potent vasodilator of rat and human resistance arteries. Am. J. Physiol. Heart Circ. Physiol., 2008, 294(3), H1381-H1387.
117. Kim, S.Y.; Ryu, H.M.; Yang, J.H.; Kim, M.Y.; Han, J.Y.; Kim, J.O.; Chung, J.H.; Park, S.Y.; Lee, M.H.; Kim, D.J. Increased sFlt-1 to PlGF ratio in women who subsequently develop preeclampsia. J. Korean Med. Sci., 2007, 22(5), 873-877.
118. Conrad, K.P.; Miles, T.M.; Benyo, D.F. Circulating levels of immunoreactive cytokines in women with preeclampsia. Am. J. Reprod. Immunol., 1998, 40(2), 102-111.
119. Hashii, K.; Fujiwara, H.; Yoshioka, S.; Kataoka, N.; Yamada, S.; Hirano, T.; Mori, T.; Fujii, S.; Maeda, M. Peripheral blood mononuclear cells stimulate progesterone production by luteal cells derived from pregnant and non-pregnant women: possible involvement of interleukin-4 and interleukin-10 in corpus luteum function and differentiation. Hum. Reprod., 1998, 13(10), 2738-2744.
120. Alexander, B.T.; Cockrell, K.L.; Massey, M.B.; Bennett, W.A.; Granger, J.P. Tumor necrosis factor-alpha-induced hypertension in pregnant rats results in decreased renal neuronal nitric oxide synthase expression. Am. J. Hypertens., 2002, 15(2 Pt 1), 170-175.
121. Takagi, Y.; Nikaido, T.; Toki, T.; Kita, N.; Kanai, M.; Ashida, T.; Ohira, S.; Konishi, I. Levels of oxidative stress and redox-related molecules in the placenta in preeclampsia and fetal growth restriction. Virchows Arch., 2004, 444(1), 49-55.
122. Walsh, S.W. Eicosanoids in preeclampsia. Prostaglandins Leukot. Essent. Fatty Acids, 2004, 70(2), 223-232.
123. Nakamura, M.; Sekizawa, A.; Purwosunu, Y.; Okazaki, S.; Farina, A.; Wibowo, N.; Shimizu, H.; Okai, T. Cellular mRNA expressions of anti-oxidant factors in the blood of preeclamptic women. Prenat. Diagn., 2009, 29(7), 691-696.
124. Yung, H.W.; Calabrese, S.; Hynx, D.; Hemmings, B.A.; Cetin, I.; Charnock-Jones, D.S.; Burton, G.J. Evidence of placental translation inhibition and endoplasmic reticulum stress in the etiology of human intrauterine growth restriction. Am. J. Pathol., 2008, 173(2), 451-462.
125. Egi, K.; Conrad, N.E.; Kwan, J.; Schulze, C.; Schulz, R.; Wildhirt, S.M. Inhibition of inducible nitric oxide synthase and superoxide production reduces matrix metalloproteinase-9 activity and restores coronary vasomotor function in rat cardiac allografts. Eur. J. Cardiothorac. Surg., 2004, 26(2), 262-269.
126. Chang, T.C.; Huang, C.J.; Tam, K.; Chen, S.F.; Tan, K.T.; Tsai, M.S.; Lin, T.N.; Shyue, S.K. Stabilization of hypoxia-inducible factor-1{alpha} by prostacyclin under prolonged hypoxia via reducing reactive oxygen species level in endothelial cells. J. Biol. Chem., 2005, 280(44), 36567-36574.
127. Jin, L.; Ying, Z.; Webb, R.C. Activation of Rho/Rho kinase signaling pathway by reactive oxygen species in rat aorta. Am. J. Physiol. Heart Circ. Physiol., 2004, 287(4), H1495-1500.
128. Semenza, G.L. Hypoxia-inducible factor 1: control of oxygen homeostasis in health and disease. Pediatr. Res., 2001, 49(5), 614-617.
129. Ke, Q.; Costa, M. Hypoxia-inducible factor-1 (HIF-1). Mol. Pharmacol., 2006, 70(5), 1469-1480.
130. Cockman, M.E.; Masson, N.; Mole, D.R.; Jaakkola, P.; Chang, G.W.; Clifford, S.C.; Maher, E.R.; Pugh, C.W.; Ratcliffe, P.J.; Maxwell, P.H. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem., 2000, 275(33), 25733-25741.
131. Yamashita, K.; Discher, D.J.; Hu, J.; Bishopric, N.H.; Webster, K.A. Molecular regulation of the endothelin-1 gene by hypoxia. Contributions of hypoxia-inducible factor-1, activator protein-1, GATA-2, AND p300/CBP. J. Biol. Chem., 2001, 276(16), 12645-12653.
132. Suzuki, S.; Gejyo, F.; Ogino, S.; Maruyama, Y.; Ueno, M.; Nishi, S.; Kimura, H.; Arakawa, M. Postpartum renal lesions in women with pre-eclampsia. Nephrol. Dial. Transplant, 1997, 12(12), 2488-2493.
133. Bar, J.; Kaplan, B.; Wittenberg, C.; Erman, A.; Boner, G.; Ben-Rafael, Z.; Hod, M. Microalbuminuria after pregnancy complicated by pre-eclampsia. Nephrol. Dial. Transplant, 1999, 14(5), 1129-1132.
134. Stillman, I.E.; Karumanchi, S.A. The glomerular injury of preeclampsia. J. Am. Soc. Nephrol., 2007, 18(8), 2281-2284.
135. Sladek, S.M.; Magness, R.R.; Conrad, K.P. Nitric oxide and pregnancy. Am. J. Physiol., 1997, 272(2 Pt 2), R441-R463.
136. Nelson, S.H.; Steinsland, O.S.; Wang, Y.; Yallampalli, C.; Dong, Y.L.; Sanchez, J.M. Increased nitric oxide synthase activity and expression in the human uterine artery during pregnancy. Circ. Res., 2000, 87(5), 406-411.
137. Conrad, K.P.; Kerchner, L.J.; Mosher, M.D. Plasma and 24-h NO(x) and cGMP during normal pregnancy and preeclampsia in women on a reduced NO(x) diet. Am. J. Physiol., 1999, 277(1 Pt 2), F48-57.
138. Mutlu-Turkoglu, U.; Aykac-Toker, G.; Ibrahimoglu, L.; Ademoglu, E.; Uysal, M. Plasma nitric oxide metabolites and lipid peroxide levels in preeclamptic pregnant women before and after delivery. Gynecol. Obstet. Invest., 1999, 48(4), 247-250.
139. Schiessl, B.; Mylonas, I.; Kuhn, C.; Kunze, S.; Schulze, S.; Friese, K.; Jeschke, U. Expression of estrogen receptor-alpha, estrogen receptor-beta and placental endothelial and inducible NO synthase in intrauterine growth-restricted and normal placentals. Arch. Med. Res., 2006, 37(8), 967-975.
140. Roberts, J.M. Endothelial dysfunction in preeclampsia. Semin. Reprod. Endocrinol., 1998, 16(1), 5-15.
141. Khalil, R.A.; Crews, J.K.; Novak, J.; Kassab, S.; Granger, J.P. Enhanced vascular reactivity during inhibition of nitric oxide synthesis in pregnant rats. Hypertension, 1998, 31(5), 1065-1069.
142. Suzuki, Y.; Hattori, T.; Kajikuri, J.; Yamamoto, T.; Suzumori, K.; Itoh, T. Reduced function of endothelial prostacyclin in human omental resistance arteries in pre-eclampsia. J. Physiol., 2002, 545(Pt 1), 269-277.
143. Fike, C.D.; Kaplowitz, M.R.; Pfister, S.L. Arachidonic acid metabolites and an early stage of pulmonary hypertension in chronically hypoxic newborn pigs. Am. J. Physiol. Lung Cell Mol. Physiol., 2003, 284(2), L316-323.
144. Bowen, R.S.; Zhang, Y.; Gu, Y.; Lewis, D.F.; Wang, Y. Increased phospholipase A2 and thromboxane but not prostacyclin production by placental trophoblast cells from normal and preeclamptic pregnancies cultured under hypoxia condition. Placenta, 2005, 26(5), 402-409.
145. Zhao, S.; Gu, Y.; Lewis, D.F.; Wang, Y. Predominant basal directional release of thromboxane, but not prostacyclin, by placental trophoblasts from normal and preeclamptic pregnancies. Placenta, 2008, 29(1), 81-88.
146. Scotland, R.S.; Madhani, M.; Chauhan, S.; Moncada, S.; Andresen, J.; Nilsson, H.; Hobbs, A.J.; Ahluwalia, A. Investigation of vascular responses in endothelial nitric oxide synthase/cyclooxygenase-1 double-knockout mice: key role for endothelium-derived hyperpolarizing factor in the regulation of blood pressure in vivo. Circulation, 2005, 111(6), 796-803.
147. Luksha, L.; Nisell, H.; Luksha, N.; Kublickas, M.; Hultenby, K.; Kublickiene, K. Endothelium-derived hyperpolarizing factor in preeclampsia: heterogeneous contribution, mechanisms, and morphological prerequisites. Am. J. Physiol. Regul. Integr. Comp.Physiol., 2008, 294(2), R510-R519.
148. Fulep, E.E.; Vedernikov, Y.P.; Saade, G.R.; Garfield, R.E. The role of endothelium-derived hyperpolarizing factor in the regulation of the uterine circulation in pregnant rats. Am. J. Obstet. Gynecol., 2001, 185(3), 638-642.
149. Niwano, K.; Arai, M.; Tomaru, K.; Uchiyama, T.; Ohyama, Y.; Kurabayashi, M. Transcriptional stimulation of the eNOS gene by the stable prostacyclin analogue beraprost is mediated through cAMP-responsive element in vascular endothelial cells: close link between PGI2 signal and NO pathways. Circ. Res., 2003, 93(6), 523-530.
150. Orie, N.N.; Fry, C.H.; Clapp, L.H. Evidence that inward rectifier K+ channels mediate relaxation by the PGI2 receptor agonist cicaprostvia a cyclic AMP-independent mechanism. Cardiovasc. Res., 2006, 69(1), 107-115.
151. Kourembanas, S.; McQuillan, L.P.; Leung, G.K.; Faller, D.V. Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia. J. Clin. Invest., 1993, 92(1), 99-104.
152. Taylor, R.N.; Varma, M.; Teng, N.N.; Roberts, J.M. Women with preeclampsia have higher plasma endothelin levels than women with normal pregnancies. J. Clin. Endocrinol. Metab., 1990, 71(6), 1675-1677.
153. McNair, L.L.; Salamanca, D.A.; Khalil, R.A. Endothelin-1 promotes Ca2+ antagonist-insensitive coronary smooth muscle contraction via activation of epsilon-protein kinase C. Hypertension, 2004, 43(4), 897-904.
154. Giardina, J.B.; Green, G.M.; Rinewalt, A.N.; Granger, J.P.; Khalil, R.A. Role of endothelin B receptors in enhancing endotheliumdependent nitric oxide-mediated vascular relaxation during high salt diet. Hypertension, 2001, 37(2 Part 2), 516-523.
155. Conrad, K.P.; Gandley, R.E.; Ogawa, T.; Nakanishi, S.; Danielson, L.A. Endothelin mediates renal vasodilation and hyperfiltration during pregnancy in chronically instrumented conscious rats. Am. J. Physiol., 1999, 276(5 Pt 2), F767-776.
156. Debrah, D.O.; Novak, J.; Matthews, J.E.; Ramirez, R.J.; Shroff, S.G.; Conrad, K.P. Relaxin is essential for systemic vasodilation and increased global arterial compliance during early pregnancy in conscious rats. Endocrinology, 2006, 147(11), 5126-5131.
157. Yang, G.; Chang, L.; Alexander, J.S.; Groome, L.J.; Yuping, W. Chymotrypsin-like protease (chymase) mediates endothelial activation by factors derived from preeclamptic placentas. Reprod. Sci., 2009, 16(9), 905-913.
158. Cheng, Z.J.; Vapaatalo, H.; Mervaala, E. Angiotensin II and vascular inflammation. Med. Sci. Monit., 2005, 11(6), RA194-RA205.
159. Askari, B.; Ferreri, N.R. Regulation of prostacyclin synthesis by angiotensin II and TNF-alpha in vascular smooth muscle. Prostaglandins Other Lipid Mediat., 2001, 63(4), 175-187.
160. Wesselman, J.P.; De Mey, J.G. Angiotensin and cytoskeletal proteins: role in vascular remodeling. Curr. Hypertens. Rep., 2002, 4(1), 63-70.
161. Wijayagunawardane, M.P.; Gabler, C.; Killian, G.; Miyamoto, A. Tumor necrosis factor alpha in the bovine oviduct during the estrous cycle: messenger RNA expression and effect on secretion of prostaglandins, endothelin-1, and angiotensin II. Biol. Reprod., 2003, 69(4), 1341-1346.
162. Wassmann, S.; Stumpf, M.; Strehlow, K.; Schmid, A.; Schieffer, B.; Bohm, M.; Nickenig, G. Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ. Res., 2004, 94(4), 534-541.
163. Anguiano-Robledo, L.; Reyes-Melchor, P.A.; Bobadilla-Lugo, R.A.; Perez-Alvarez, V.M.; Lopez-Sanchez, P. Renal angiotensin-II receptors expression changes in a model of preeclampsia. Hypertens. Pregnancy, 2007, 26(2), 151-161.
164. AbdAlla, S.; Abdel-Baset, A.; Lother, H.; el Massiery, A.; Quitterer, U. Mesangial AT1/B2 receptor heterodimers contribute to angiotensin II hyperresponsiveness in experimental hypertension. J. Mol. Neurosci., 2005, 26(2-3), 185-192.
165. Anton, L.; Merrill, D.C.; Neves, L.A.; Diz, D.I.; Corthorn, J.; Valdes, G.; Stovall, K.; Gallagher, P.E.; Moorefield, C.; Gruver, C.; Brosnihan, K.B. The uterine placental bed Renin-Angiotensin system in normal and preeclamptic pregnancy. Endocrinology, 2009, 150(9), 4316-4325.
166. Zhou, C.C.; Ahmad, S.; Mi, T.; Abbasi, S.; Xia, L.; Day, M.C.; Ramin, S.M.; Ahmed, A.; Kellems, R.E.; Xia, Y. Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/ nuclear factor of activated T-cells signaling. Hypertension, 2008, 51(4), 1010-1019.
167. Bobst, S.M.; Day, M.C.; Gilstrap, L.C., 3rd; Xia, Y.; Kellems, R.E. Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human mesangial cells and induce interleukin-6 and plasminogen activator inhibitor-1 secretion. Am. J. Hypertens., 2005, 18(3), 330-336.
168. Bakker, W.W.; Henning, R.H.; van Son, W.J.; van Pampus, M.G.; Aarnoudse, J.G.; Niezen-Koning, K.E.; Borghuis, T.; Jongman, R.M.; van Goor, H.; Poelstra, K.; Navis, G.; Faas, M.M. Vascular contraction and preeclampsia: downregulation of the Angiotensin receptor 1 by hemopexin in vitro. Hypertension, 2009, 53(6), 959-964.
169. Koba, S.; Pakala, R.; Watanabe, T.; Katagiri, T.; Benedict, C.R. Synergistic interaction between thromboxane A2 and mildly oxidized low density lipoproteins on vascular smooth muscle cell proliferation. Prostaglandins Leukot. Essent. Fatty Acids, 2000, 63(6), 329-335.
170. Knight, M.; Duley, L.; Henderson-Smart, D.J.; King, J.F. Antiplatelet agents for preventing and treating pre-eclampsia. Cochrane Database Syst. Rev., 2000, (2), CD000492.
171. Coomarasamy, A.; Honest, H.; Papaioannou, S.; Gee, H.; Khan, K.S. Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review. Obstet. Gynecol., 2003, 101(6), 1319-1332.
172. Seki, H.; Kuromaki, K.; Takeda, S.; Kinoshita, K.; Satoh, K. Trial of prophylactic administration of TXA2 synthetase inhibitor, ozagrel hydrochloride, for preeclampsia. Hypertens. Pregnancy, 1999, 18(2), 157-164.
173. Horowitz, A.; Menice, C.B.; Laporte, R.; Morgan, K.G. Mechanisms of smooth muscle contraction. Physiol. Rev., 1996, 76(4), 967-1003.
174. Wimalasundera, R.C.; Thom, S.A.; Regan, L.; Hughes, A.D. Effects of vasoactive agents on intracellular calcium and force in myometrial and subcutaneous resistance arteries isolated from preeclamptic, pregnant, and nonpregnant woman. Am. J. Obstet. Gynecol., 2005, 192(2), 625-632.
175. Kanashiro, C.A.; Cockrell, K.L.; Alexander, B.T.; Granger, J.P.; Khalil, R.A. Pregnancy-associated reduction in vascular protein kinase C activity rebounds during inhibition of NO synthesis. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2000, 278(2), R295-R303.
176. Farley, D.B.; Ford, S.P. Evidence for declining extracellular calcium uptake and protein kinase C activity in uterine arterial smooth muscle during gestation in gilts. Biol. Reprod., 1992, 46(3), 315-321.
177. Salamanca, D.A.; Khalil, R.A. Protein kinase C isoforms as specific targets for modulation of vascular smooth muscle function in hypertension. Biochem. Pharmacol., 2005, 70(11), 1537-1547.
178. Van Wijk, M.J.; Boer, K.; van der Meulen, E.T.; Bleker, O.P.; Spaan, J.A.; VanBavel, E. Resistance artery smooth muscle function in pregnancy and preeclampsia. Am. J. Obstet. Gynecol., 2002, 186(1), 148-154.
179. Wallukat, G.; Homuth, V.; Fischer, T.; Lindschau, C.; Horstkamp, B.; Jupner, A.; Baur, E.; Nissen, E.; Vetter, K.; Neichel, D.; Dudenhausen, J.W.; Haller, H.; Luft, F.C. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J. Clin. Invest., 1999, 103(7), 945-952.
180. Hu, E. Recent patents on Rho signaling pathway as therapeutic target for cardiovascular diseases. Recent Pat. Cardiovasc. Drug Discov., 2006, 1(3), 249-263.
181. Kataoka, C.; Egashira, K.; Inoue, S.; Takemoto, M.; Ni, W.; Koyanagi, M.; Kitamoto, S.; Usui, M.; Kaibuchi, K.; Shimokawa, H.; Takeshita, A. Important role of Rho-kinase in the pathogenesis of cardiovascular inflammation and remodeling induced by long-term blockade of nitric oxide synthesis in rats. Hypertension, 2002, 39(2), 245-250.
182. Friel, A.M.; Sexton, D.J.; O'Reilly, M.W.; Smith, T.J.; Morrison, J.J. Rho A/Rho kinase: human umbilical artery mRNA expression in normal and pre eclamptic pregnancies and functional role in isoprostane-induced vasoconstriction. Reproduction, 2006, 132(1), 169-176.
183. Raines, E.W. The extracellular matrix can regulate vascular cell migration, proliferation, and survival: relationships to vascular disease. Int. J. Exp. Pathol., 2000, 81(3), 173-182.
184. Tayebjee, M.H.; Lip, G.Y.; Blann, A.D.; Macfadyen, R.J. Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2. Thromb. Res., 2005, 115(3), 205-210.
185. Sternlicht, M.D.; Werb, Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol., 2001, 17, 463-516.
186. Raffetto, J.D.; Qiao, X.; Koledova, V.V.; Khalil, R.A. Prolonged increases in vein wall tension increase matrix metalloproteinases and decrease constriction in rat vena cava: Potential implications in varicose veins. J. Vasc. Surg., 2008, 48(2), 447-456.
187. McCawley, L.J.; Matrisian, L.M. Matrix metalloproteinases: they're not just for matrix anymore! Curr. Opin. Cell Biol., 2001, 13(5), 534-540.
188. Jeyabalan, A.; Novak, J.; Doty, K.D.; Matthews, J.; Fisher, M.C.; Kerchner, L.J.; Conrad, K.P. Vascular matrix metalloproteinase-9 mediates the inhibition of myogenic reactivity in small arteries isolated from rats after short-term administration of relaxin. Endocrinology, 2007, 148(1), 189-197.
189. Kelly, B.A.; Bond, B.C.; Poston, L. Aortic adaptation to pregnancy: levated expression of matrix metalloproteinases-2 and -3 in rat gestation. Mol. Hum. Reprod., 2004, 10(5), 331-337.
190. Galewska, Z.; Bankowski, E.; Romanowicz, L.; Jaworski, S. Preeclampsia (EPH-gestosis)-induced decrease of MMP-s content in the umbilical cord artery. Clin. Chim. Acta, 2003, 335(1-2), 109-115.
191. Chew, D.K.; Conte, M.S.; Khalil, R.A. Matrix metalloproteinasespecific inhibition of Ca2+ entry mechanisms of vascular contraction. J. Vasc. Surg., 2004, 40(5), 1001-1010.
192. Wang, H.; Olszewski, B.; Rosebury, W.; Wang, D.; Robertson, A.; Keiser, J.A. Impaired angiogenesis in SHR is associated with decreased KDR and MT1-MMP expression. Biochem. Biophys. Res. Commun., 2004, 315(2), 363-368.
193. MacKay, A.P.; Berg, C.J.; Atrash, H.K. Pregnancy-related mortality from preeclampsia and eclampsia. Obstet. Gynecol., 2001, 97(4), 533-538.
194. von Dadelszen, P.; Magee, L.A.; Roberts, J.M. Subclassification of preeclampsia. Hypertens. Pregnancy, 2003, 22(2), 143-148.
195. Grill, S.; Rusterholz, C.; Zanetti-Dallenbach, R.; Tercanli, S.; Holzgreve, W.; Hahn, S.; Lapaire, O. Potential markers of preeclampsia--a review. Reprod. Biol. Endocrinol., 2009, 7, 70.
196. Purwosunu, Y.; Sekizawa, A.; Okazaki, S.; Farina, A.; Wibowo, N.; Nakamura, M.; Rizzo, N.; Saito, H.; Okai, T. Prediction of preeclampsia by analysis of cell-free messenger RNA in maternal plasma. Am. J. Obstet. Gynecol., 2009, 200(4), 386, e381-e387.
197. Lim, J.H.; Kim, S.Y.; Park, S.Y.; Yang, J.H.; Kim, M.Y.; Ryu, H.M. Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors. Obstet. Gynecol., 2008, 111(6), 1403-1409.
198. Baumann, M.U.; Bersinger, N.A.; Mohaupt, M.G.; Raio, L.; Gerber, S.; Surbek, D.V. First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia. Am. J. Obstet. Gynecol., 2008, 199(3), 266. e1-e6.
199. Verlohren, S.; Galindo, A.; Schlembach, D.; Zeisler, H.; Herraiz, I.; Moertl, M.G.; Pape, J.; Dudenhausen, J.W.; Denk, B.; Stepan, H. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am. J. Obstet. Gynecol., 202(2), 161. e1-e161. e11.
200. Tripathi, R.; Rath, G.; Ralhan, R.; Saxena, S.; Salhan, S. Soluble and membranous vascular endothelial growth factor receptor-2 in pregnancies complicated by pre-eclampsia. Yonsei. Med. J., 2009, 50(5), 656-666.
201. Banzola, I.; Farina, A.; Concu, M.; Sekizawa, A.; Purwosunu, Y.; Strada, I.; Arcelli, D.; Simonazzi, G.; Caramelli, E.; Rizzo, N. Performance of a panel of maternal serum markers in predictingpreeclampsia at 11-15 weeks' gestation. Prenat. Diagn., 2007,27(11), 1005-1010.
202. Chavarria, M.E.; Lara-Gonzalez, L.; Garcia-Paleta, Y.; Vital-Reyes, V.S.; Reyes, A. Adhesion molecules changes at 20 gestation weeks in pregnancies complicated by preeclampsia. Eur. J. Obstet. Gynecol. Reprod. Biol., 2008, 137(2), 157-164.
203. Zeng, X.; Sun, Y.; Yang, H.X.; Li, D.; Li, Y.X.; Liao, Q.P.; Wang, Y.L. Plasma level of soluble c-Met is tightly associated with theclinical risk of preeclampsia. Am. J. Obstet. Gynecol., 2009, 201(6), 618. e1-e7.
204. Spencer, K.; Cowans, N.J.; Stamatopoulou, A. ADAM12s in maternal serum as a potential marker of pre-eclampsia. Prenat. Diagn., 2008, 28(3), 212-216.
205. Poon, L.C.; Maiz, N.; Valencia, C.; Plasencia, W.; Nicolaides, K.H. First-trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia. Ultrasound Obstet. Gynecol., 2009, 33(1), 23-33.
206. Adali, E.; Yildizhan, R.; Kolusari, A.; Kurdoglu, M.; Bugdayci, G.; Sahin, H.G.; Kamaci, M. Increased visfatin and leptin in pregnancies complicated by pre-eclampsia. J. Matern. Fetal Neonatal Med., 2009, 22(10), 873-879.
207. Hu, W.; Wang, Z.; Wang, H.; Huang, H.; Dong, M. Serum visfatin levels in late pregnancy and pre-eclampsia. Acta Obstet. Gynecol. Scand., 2008, 87(4), 413-418.
208. Senna, A.A.; Zedan, M.; el-Salam, G.E.; el-Mashad, A.I. Study of plasma adrenomedullin level in normal pregnancy and preclampsia. Medscape J. Med., 2008, 10(2), 29.
209. Khalil, A.; Cowans, N.J.; Spencer, K.; Goichman, S.; Meiri, H.; Harrington, K. First trimester maternal serum placental protein 13 for the prediction of pre-eclampsia in women with a priori high risk. Prenat Diagn., 2009, 29(8), 781-789.
210. Spencer, K.; Cowans, N.J.; Nicolaides, K.H. Maternal serum inhibin-A and activin-A levels in the first trimester of pregnancies developing pre-eclampsia. Ultrasound Obstet. Gynecol., 2008, 32(5), 622-626.
211. Armstrong, R.A.; Reynolds, R.M.; Leask, R.; Shearing, C.H.; Calder, A.A.; Riley, S.C. Decreased serum levels of kisspeptin in early pregnancy are associated with intra-uterine growth restriction and pre-eclampsia. Prenat. Diagn., 2009, 29(10), 982-985.
212. Lynch, A.M.; Murphy, J.R.; Byers, T.; Gibbs, R.S.; Neville, M.C.; Giclas, P.C.; Salmon, J.E.; Holers, V.M. Alternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia. Am. J. Obstet. Gynecol., 2008, 198(4), 385, e1-e9.
213. Greer, I.A.; Haddad, N.G.; Dawes, J.; Johnstone, F.D.; Calder, A.A. Neutrophil activation in pregnancy-induced hypertension. Br. J. Obstet. Gynaecol., 1989, 96(8), 978-982.
214. Crocker, I.P.; Wellings, R.P.; Fletcher, J.; Baker, P.N. Neutrophil function in women with pre-eclampsia. Br. J. Obstet. Gynaecol., 1999, 106(8), 822-828.
215. Sabatier, F.; Bretelle, F.; D'Ercole, C.; Boubli, L.; Sampol, J.; Dignat-George, F. Neutrophil activation in preeclampsia and isolated intrauterine growth restriction. Am. J. Obstet. Gynecol., 2000, 183(6), 1558-1563.
216. Mellembakken, J.R.; Aukrust, P.; Olafsen, M.K.; Ueland, T.; Hestdal, K.; Videm, V. Activation of leukocytes during the uteroplacental passage in preeclampsia. Hypertension, 2002, 39(1), 155-160.
217. Redman, C.W.; Sacks, G.P.; Sargent, I.L. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am. J. Obstet. Gynecol., 1999, 180(2 Pt 1), 499-506.
218. Wang, Y.; Gu, Y.; Philibert, L.; Lucas, M.J. Neutrophil activation induced by placental factors in normal and pre-eclamptic pregnancies in vitro. Placenta, 2001, 22(6), 560-565.
219. Dundar, O.; Yoruk, P.; Tutuncu, L.; Erikci, A.A.; Muhcu, M.; Ergur, A.R.; Atay, V.; Mungen, E. Longitudinal study of platelet size changes in gestation and predictive power of elevated MPV in development of pre-eclampsia. Prenat. Diagn., 2008, 28(11), 1052-1056.
220. Powers, R.W.; Bodnar, L.M.; Ness, R.B.; Cooper, K.M.; Gallaher, M.J.; Frank, M.P.; Daftary, A.R.; Roberts, J.M. Uric acid concentrations in early pregnancy among preeclamptic women with gestational hyperuricemia at delivery. Am. J. Obstet. Gynecol., 2006, 194(1), 160.
221. Many, A.; Hubel, C.A.; Roberts, J.M. Hyperuricemia and xanthine oxidase in preeclampsia, revisited. Am. J. Obstet. Gynecol., 1996, 174(1 Pt 1), 288-291.
222. Bainbridge, S.A.; Roberts, J.M.; von Versen-Hoynck, F.; Koch, J.; Edmunds, L.; Hubel, C.A. Uric acid attenuates trophoblast invasion and integration into endothelial cell monolayers. Am. J. Physiol. Cell Physiol., 2009, 297(2), C440-450.
223. Koopmans, C.M.; van Pampus, M.G.; Groen, H.; Aarnoudse, J.G.; van den Berg, P.P.; Mol, B.W. Accuracy of serum uric acid as a predictive test for maternal complications in pre-eclampsia: bivariate meta-analysis and decision analysis. Eur. J. Obstet. Gynecol. Reprod. Biol., 2009, 146(1), 8-14.
224. Anand-Ivell, R.; Ivell, R.; Driscoll, D.; Manson, J. Insulin-like factor 3 levels in amniotic fluid of human male fetuses. Hum. Reprod., 2008, 23(5), 1180-1186.
225. Kim, S.Y.; Ryu, H.M.; Yang, J.H.; Kim, M.Y.; Ahn, H.K.; Shin, J.S.; Choi, J.S.; Park, S.Y.; Kim, J.M.; Lee, B.Y.; Kim, D.J. Maternal serum and amniotic fluid inhibin A levels in women who subsequently develop severe preeclampsia. J. Korean Med. Sci., 2006,21(3), 452-456.
226. Staff, A.C.; Braekke, K.; Harsem, N.K.; Lyberg, T.; Holthe, M.R. Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia. Eur. J. Obstet. Gynecol. Reprod. Biol., 2005, 122(1), 33-39.
227. Hunt, B.J.; Missfelder-Lobos, H.; Parra-Cordero, M.; Fletcher, O.; Parmar, K.; Lefkou, E.; Lees, C.C. Pregnancy outcome and fibrinolytic, endothelial and coagulation markers in women undergoing uterine artery Doppler screening at 23 weeks. J. Thromb. Haemost., 2009, 7(6), 955-961.
228. Facchinetti, F.; Saade, G.R.; Neri, I.; Pizzi, C.; Longo, M.; Volpe, A. L-arginine supplementation in patients with gestational hypertension: a pilot study. Hypertens. Pregnancy, 2007, 26(1), 121-130.
229. Hladunewich, M.A.; Derby, G.C.; Lafayette, R.A.; Blouch, K.L.; Druzin, M.L.; Myers, B.D. Effect of L-arginine therapy on the glomerular injury of preeclampsia: a randomized controlled trial. Obstet. Gynecol., 2006, 107(4), 886-895.
230. Kulier, R.; de Onis, M.; Gulmezoglu, A.M.; Villar, J. Nutritional interventions for the prevention of maternal morbidity. Int. J. Gynaecol. Obstet., 1998, 63(3), 231-246.
231. Olsen, S.F.; Secher, N.J.; Bjornsson, S.; Weber, T.; Atke, A. The potential benefits of using fish oil in relation to preterm labor: the case for a randomized controlled trial? Acta Obstet. Gynecol. Scand., 2003, 82(11), 978-982.
232. Kupferminc, M.J.; Fait, G.; Many, A.; Lessing, J.B.; Yair, D.; Bar-Am, A.; Eldor, A. Low-molecular-weight heparin for the prevention of obstetric complications in women with thrombophilias. Hypertens. Pregnancy, 2001, 20(1), 35-44.
233. Rumbold, A.R.; Crowther, C.A.; Haslam, R.R.; Dekker, G.A.; Robinson, J.S. Vitamins C and E and the risks of preeclampsia and perinatal complications. N. Engl. J. Med., 2006, 354(17), 1796-1806.
234. Magee, L.A.; Abalos, E.; von Dadelszen, P.; Sibai, B.; Walkinshaw, S.A. Control of hypertension in pregnancy. Curr. Hypertens. Rep., 2009, 11(6), 429-436.
235. Lowe, S.A.; Brown, M.A.; Dekker, G.A.; Gatt, S.; McLintock, C.K.; McMahon, L.P.; Mangos, G.; Moore, M.P.; Muller, P.; Paech, M.; Walters, B. Guidelines for the management of hypertensive disorders of pregnancy 2008. Aust. NZJ Obstet. Gynaecol., 2009, 49(3), 242-246.
236. Duckitt, K.; Harrington, D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ, 2005, 330(7491), 565.
237. Sela, S.; Itin, A.; Natanson-Yaron, S.; Greenfield, C.; Goldman-Wohl, D.; Yagel, S.; Keshet, E. A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia. Circ. Res., 2008, 102(12), 1566-1574.
238. Laverriere, A.; Landau, R.; Charvet, I.; Irion, O.; Bischof, P.; Morales, M.; Cohen, M. GRP78 as a marker of pre-eclampsia: an exploratory study. Mol. Hum. Reprod., 2009, 15(9), 569-574.
239. Disentangling fetal and maternal susceptibility for pre-eclampsia: a British multicenter candidate-gene study. Am. J. Hum. Genet., 2005, 77(1), 127-131.